February 8, 2011

AMT to Release Full Year 2010 Results on Wednesday February 16, 2011

AMSTERDAM, February 8, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular
Therapeutics (Euronext: AMT), a leader in the field of human gene therapy,
announced today that it will release its financial results for the year ended
December 31, 2010 on Wednesday, February 16, 2011 at 07:00 AM Central
European Time (CET). To discuss these results, AMT's management will conduct
a conference call at 3:30 PM CET, which will also be webcast.

To participate in the conference call, please call one of the following
telephone numbers 15 minutes prior to the event, using access code 3705648:
+44(0)20-7806-1956 for the UK; +1-212-444-0413 for the US; and
+31(0)20-707-5510 for the Netherlands. Following the results presentation,
the lines will be opened for a question and answer session. A replay of the
call will be available following the event.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies.
The company's lead product Glybera(R), a gene therapy for the treatment of
lipoprotein lipase deficiency (LPLD), is currently under review by the
European Medicines Agency (EMA). If approved, Glybera will be the first gene
therapy product to be marketed in Europe. AMT also has a product pipeline of
several gene therapy products in development for hemophilia B, Duchenne
muscular dystrophy, acute intermittent porphyria, and Parkinson's disease.
Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of
choice for therapeutic genes, the company has been able to design and
validate probably the world's first stable and scalable AAV manufacturing
platform. This proprietary platform can be applied to a large number of rare
(orphan) diseases caused by one faulty gene and allows AMT to pursue its
strategy of focusing on this sector of the industry. AMT was founded in 1998
and is based in Amsterdam. Further information can be found at

SOURCE Amsterdam Molecular Therapeutics B.V